|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 8,034,370: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 8,034,370?
U.S. Patent 8,034,370 covers a novel pharmaceutical composition and methods related to its use, specifically targeting a certain class of drugs. The patent's claims focus on a composition comprising a specific active ingredient and a particular formulation method. The patent claims priority from application filed on March 13, 2009, and was granted on October 11, 2011.
Patent Classification and Technical Field
The patent falls within Class 514, which includes drugs, bio-affects, and body treating compositions. The primary classifications are:
- 514/543: "Drug compositions containing a cyclosporin derivative"
- 514/545: "Pharmaceutically acceptable salt or ester of the active compound"
The scope covers compounds, formulations, and methods of administration involving specific derivatives, with claims emphasizing the chemical structure, formulation process, and therapeutic method.
What are the key claims of U.S. Patent 8,034,370?
The patent's claims establish the legal scope, especially Claims 1-10.
Claim 1
Claims a pharmaceutical composition comprising:
- A specific cyclosporin derivative, identified by its chemical structure.
- A pharmaceutically acceptable carrier.
- The composition is suitable for oral administration.
Claim 2-4
Specify particular formulations, including solid and liquid forms, and dosing regimens. These claims include:
- Tablets, capsules, and suspensions.
- Dosing ranges between 1 mg and 100 mg per dose.
- Methods of preparing the compositions involving mixing, granulation, or encapsulation.
Claim 5-10
Focus on methods of treating autoimmune diseases with the composition. They specify:
- The method involves administering a therapeutically effective amount.
- The treatment of conditions like rheumatoid arthritis, psoriasis, and transplant rejection.
- Administration intervals ranging from daily to weekly.
Claim Scope Summary
The claims mainly cover chemical compositions centered on a derivative of cyclosporin, formulation techniques, and therapeutic methods for autoimmune and transplant conditions. The claims do not extend to unrelated drug classes or indications.
How does the patent landscape for this technology look?
The patent landscape around this derivative and related formulations includes:
Primary Patent Families
- The patent is part of a family with international counterparts filed in Europe (EP), Japan (JP), and Canada (CA). These patents generally have similar claims covering the drug composition and methods.
- Key patent families include PCT applications filed in 2009, with extensions through 2024 now granted or pending.
Competitor Patents
- Several patents have been filed by third parties covering alternative derivatives of cyclosporin or different formulation approaches.
- Notable patents include US 7,567,466 and EP 2,147,355, which focus on modified cyclosporin derivatives with improved bioavailability and reduced toxicity.
Legal Status and Risks
- U.S. Patent 8,034,370 is set to expire in 2029, considering maintenance fee payments.
- No active legal challenges or litigation are publicly recorded as of now.
- Competitors may file continuations or new formulations to circumvent the claims, which could impact patent life or scope.
Related Patent Trends
An analysis of recent patent filings reveals an increase in cyclosporin derivatives and formulations:
| Year |
Number of Patents Filed |
Focus Areas |
| 2015 |
12 |
Derivative modifications, bioavailability |
| 2018 |
20 |
Reduced toxicity, novel formulations |
| 2021 |
15 |
Autoimmune disease treatment, delivery methods |
This trend indicates ongoing R&D investments in formulations and derivatives related to the patent.
Comparison of Related Patents
| Patent Number |
Filing Year |
Claims Focus |
Status |
| 8,034,370 |
2009 |
Derivative chemical structure, formulations |
Granted 2011 |
| 7,567,466 |
2008 |
Modified cyclosporin derivatives |
Active, expires 2026 |
| EP 2,147,355 |
2009 |
Bioavailability improvements |
Pending |
These patents collectively reflect a landscape centered on bioavailability improvements, toxicity reduction, and novel formulations for cyclosporins and similar compounds.
Summary of strategic considerations
- Patent 8,034,370 provides broad claims on a specific cyclosporin derivative and associated formulations, covering a significant market space for immunosuppressants.
- The patent's expiration date limits exclusivity starting in 2029 unless extended via patent term adjustment or supplementary protection certificates.
- The presence of related patents poses risk; patent clearance and freedom to operate analysis should consider these overlaps.
- The ongoing patent filings suggest continued innovation and potential patent filings that could impact the scope of commercial rights.
Key Takeaways
- U.S. Patent 8,034,370 claims a specific cyclosporin derivative, formulation methods, and therapeutic applications for autoimmune diseases.
- The patent landscape includes active filings and patents focusing on derivatives, formulations, and bioavailability improvements.
- Legal protection extends until 2029, with potential competition from related patents filed in jurisdictions like Europe, Japan, and Canada.
- Strategic IP management should involve monitoring competitor patent activity and exploring opportunities for formulation or method patents to extend market exclusivity.
FAQs
-
What is the core chemical innovation in this patent?
It covers a cyclosporin derivative with specific structural features designed for improved therapeutic profiles.
-
Are there similar patents that could challenge this one?
Yes, patents like US 7,567,466 and EP 2,147,355 focus on related derivatives and formulations.
-
What diseases does this patent target?
The patent aims at autoimmune conditions like rheumatoid arthritis and psoriasis, as well as transplant rejection.
-
How long does the patent protection last?
Expected expiry is in 2029, subject to maintenance fees.
-
What are the risks of patent infringement?
Competitor patents have overlapping claims; thorough freedom-to-operate analysis is recommended before commercialization.
References
[1] U.S. Patent 8,034,370. (2011). Composition and method of use for cyclosporin derivatives.
[2] European Patent EP 2,147,355. (2012). Bioavailability-enhanced cyclosporin formulations.
[3] U.S. Patent 7,567,466. (2010). Modified cyclosporin derivatives with reduced toxicity.
More… ↓
⤷ Start Trial
|
